First UK operation to tackle heart failure with novel nerve-stimulating implant

August 23, 2012
This is the Cardiofit device. Credit: University of Leicester

Researchers at the University of Leicester have announced that the UK's first operation to tackle heart failure (HF) with a novel nerve-stimulating device will be performed today (Thursday August 23) at Glenfield Hospital.

The operation, which is part of a clinical trial called INOVATE-HF, could pave the way for a revolutionary treatment of a condition that scientists say has reached "epidemic proportions."

INOVATE HF is a global investigational study to determine the safety and efficacy of the CardioFit system, an implantable device designed to improve heart function in patients with HF. The study will evaluate the system's ability to reduce hospitalization and death among patients with HF, while also exploring whether combined treatment with CardioFit and prescription drug therapy is more effective than drug therapy alone.

The National Institute for Leicester Cardiovascular Unit is the first site in the UK to enrol patients in INOVATE-HF. The study's principal investigator at the site, and also the UK chief investigator, is Dr. André Ng, senior lecturer in cardiology at the University of Leicester and consultant cardiologist at Glenfield who carried out the world's first remote heart procedure using a robotic arm alongside 3-D mapping in 2010.

"Our aim with the INOVATE-HF study is to assess CardioFit's safety as well as its potential to improve heart function in patients with HF, thereby improving their quality of life and survival," said Dr. Ng. "If the hypothesis is proven in the study results, this could transform treatment and would support the use of the innovative therapy over and above tablets for standard heart failure treatment."

Heart failure is a common condition in which the heart's pumping function is compromised, leading to a cascade of limiting symptoms and poor overall body function. HF is also associated with increased mortality from sudden death as a result of dangerous heart rhythm disturbances. The condition significantly impacts the NHS due to the level of treatment required and the increased incidence of death.

In patients with HF, the nervous system is out of balance. This imbalance leads to added stress on the heart and progressive deterioration of cardiovascular function. The CardioFit system is intended to restore balance by activating a specific part of the nervous system (called the "parasympathetic" nervous system) to reduce stress on the heart, thereby alleviating HF symptoms and reversing HF deterioration. It operates by stimulating the vagus on the right side of the neck.

"This is a potentially ground-breaking treatment for desperate patients with HF, a serious condition that has increased over the past years in ," Dr. Ng said. "My University of Leicester research group has been studying the relationship between vagus nerve stimulation and for almost 15 years. It is really exciting that there is finally an innovative form of treatment available that will allow us to investigate its potential use in heart failure."

Pre-clinical data suggest that vagus nerve stimulation for the treatment of heart failure improves the function of the heart and reverses negative changes to the body associated with the condition. Moreover, the safety and performance of the CardioFit have been validated in a 32-patient, multi-centre, pilot clinical study conducted in Germany, Italy, The Netherlands and Serbia. Study data showed that patients experienced significant improvements across key clinical measures, including left ventricular function and structure, heart rate variability, and resting heart rate. Patients also showed improvement in self-reported quality of life surveys and six-minute hall walk tests. The INOVATE-HF study will broaden the research of CardioFit by enrolling more than 600 patients at up to 80 centres worldwide. The study investigates patients diagnosed with HF, aged 18 and over, who are being treated with a combination of medicines, but continue to have symptoms such as shortness of breath and fatigue.

"The INOVATE-HF study is representative of the world-class research being conducted at the University of Leicester to deliver improved patient care in hospitals," said Dr. Ng. "It epitomises the essence of good translational scientific research, where a firm scientific basis in the university lab is now applied to the clinical condition of heart failure."

Professor Huon Gray, Interim National Clinical Director for Cardiovascular Disease said:

"We know that heart failure can have a devastating effect on people's lives, so any potential advance in its treatment is to be welcomed.

"Despite a 40 percent drop in the number of deaths from heart disease over the last decade, cardiovascular disease remains a major cause of death and disability, and failure is one of the areas where we need to do more to improve results for . We are committed to supporting any work which helps us achieve this, and we welcome all such innovative research."

The INOVATE-HF study team at the University of Leicester includes Matt Bown, senior lecturer in vascular surgery; Iain Squire, professor in cardiovascular medicine; Kieran Brack, BHF intermediate basic science research fellow and research coordinator for the trial; and other members of the University Hospitals of Leicester. The study is sponsored by BioControl Medical (Yehud, Israel), the developer of the CardioFit device.

Explore further: ESC pilot registry in heart failure reflects improvement in chronic disease

Related Stories

ESC pilot registry in heart failure reflects improvement in chronic disease

August 30, 2011
With the increased prevalence of chronic heart failure (HF), there is a concomitant increase in the number of related hospitalisations; as chronic HF progresses, the risk of acute exacerbation increases.

Sexual health of men with chronic heart failure significantly improves with CRT

June 2, 2011
A new study published in the journal Clinical Cardiology reveals that in men with chronic heart failure, cardiac resynchronization therapy (CRT) improves patients' libido, erectile dysfunction, and sexual performance.

The effect of eplerenone vs. placebo on cardiovascular mortality

August 29, 2011
Today results from a new sub-analysis of the EMPHASIS-HF study showed significant reductions in death and hospitalization for five pre-defined high-risk patient sub-groups with chronic heart failure (CHF) and mild symptoms ...

EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation

May 22, 2011
The aldosterone antagonist eplerenone (Inspra, Pfizer) significantly reduced the development of new onset atrial fibrillation and flutter (AFF) in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF ...

Hospitalization for heart failure among Medicare patients has declined substantially

October 18, 2011
Between 1998 and 2008, heart-failure related hospitalizations declined substantially among Medicare patients, but at a lower rate for black men, according to a study in the October 19 issue of JAMA. Also, 1-year mortality ...

Recommended for you

Laser device placed on the heart identifies insufficient oxygenation better than other measures

September 20, 2017
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital ...

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

Which single behavior best prevents high blood pressure?

September 15, 2017
(HealthDay)—You probably already know that certain healthy lifestyle behaviors can reduce your risk of developing high blood pressure, but is any one behavior more important than the others?

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

Study shows so-called 'healthy obesity' is harmful to cardiovascular health

September 11, 2017
Clinicians are being warned not to ignore the increased cardiovascular health risks of those who are classed as either 'healthy obese' or deemed to be 'normal weight' but have metabolic abnormalities such as diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.